Hansoh Pharmaceutical Group Company Limited ( (HK:3692) ) just unveiled an update.
Hansoh Pharmaceutical Group Company Limited announced that its second Biologics License Application for XINYUE (Inebilizumab Injection) has been accepted by the National Medical Products Administration for the treatment of immunoglobulin G4-related disease. This development follows the product’s previous approval for neuromyelitis optica spectrum disorder and its inclusion in the National Reimbursement Drug List, highlighting Hansoh’s strategic positioning in the biologics market and its commitment to expanding treatment options for autoimmune diseases.
More about Hansoh Pharmaceutical Group Company Limited
Hansoh Pharmaceutical Group Company Limited is a pharmaceutical company incorporated in the Cayman Islands, focusing on the development and commercialization of innovative drugs. The company operates primarily in China’s mainland, Hong Kong, and Macao, with a market focus on biologics and treatments for neurological and autoimmune disorders.
YTD Price Performance: 4.28%
Average Trading Volume: 5,640,309
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$107B
Find detailed analytics on 3692 stock on TipRanks’ Stock Analysis page.